Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML

New England Journal of Medicine

Volumn 368, Issue 19, 2013, Pages 1781-1790

  Maxson, Julia E ^a,b   Gotlib, Jason ^e   Pollyea, Daniel A ^f   Fleischman, Angela G ^a,b   Agarwal, Anupriya ^a,b   Eide, Christopher A ^a,b,d   Bottomly, Daniel ^b   Wilmot, Beth ^b   McWeeney, Shannon K ^b   Tognon, Cristina E ^a,b,d   Pond, J Blake ^g   Collins, Robert H ^g   Goueli, Basem ^h   Stephen, T Oh ⁱ   Michael, W Deininger ^j   Chang, Bill H ^b,c   Loriaux, Marc M ^b   Druker, Brian J ^a,b,d   Tyner, Jeffrey W ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e STANFORD CANCER INSTITUTE   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h Department of Oncology and Hematology   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF UTAH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR 3; DASATINIB; JANUS KINASE; PROTEIN TNK2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RUXOLITINIB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; CANCER GENETICS; CANCER PATIENT; CHEMOSENSITIVITY; CHRONIC NEUTROPHILIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CSF3R GENE; DRUG MECHANISM; ENZYME SPECIFICITY; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC PREDISPOSITION; HETEROZYGOTE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; PRIMARY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VALIDATION PROCESS;

EID: 84877608004     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1214514     Document Type: Article

References (40)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
2. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87.
3. Bain BJ, Brunning RD, Vardiman JW, Thiele J. Chronic neutrophilic leukaemia. In: Swerdlow SH, Campo E, Lee Harris N, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press, 2008:38-9.
4. Vardiman JW, Bennett JM, Bain BJ, Brunning RD, Thiele J. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Lee Harris N, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008:80-1.
5. Froberg MK, Brunning RD, Dorion P, Litz CE, Torlakovic E. Demonstration of clonality in neutrophils using FISH in a case of chronic neutrophilic leukemia. Leukemia 1998;12:623-6.
6. Matano S, Nakamura S, Kobayashi K, Yoshida T, Matsuda T, Sugimoto T. Deletion of the long arm of chromosome 20 in a patient with chronic neutrophilic leukemia: cytogenetic findings in chronic neutrophilic leukemia. Am J Hematol 1997;54:72-5.
7. Hernández JM, del Cañizo MC, Cuneo A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 2000;11:441-4.
8. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61. [Erratum, Lancet 2005;366:122.]
9. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005;106:1207-9.
10. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
11. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-8.
12. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
13. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
14. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312-4.
15. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92:10560-4.
16. Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood 2010;115:5131-6.
17. Liu F, Wu HY, Wesselschmidt R, Kornaga T, Link DC. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity 1996;5:491-501.
18. Dong F, Brynes RK, Tidow N, Welte K, Löwenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 1995;333:487-93.
19. Dong F, Hoefsloot LH, Schelen AM, et al. Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Proc Natl Acad Sci U S A 1994;91:4480-4.
20. Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey. Blood 2007;109:93-9.
21. Beekman R, Valkhof MG, Sanders MA, et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood 2012;119:5071-7.
22. Dong F, Qiu Y, Yi T, Touw IP, Larner AC. The carboxyl terminus of the granulocyte colony-stimulating factor receptor, truncated in patients with severe congenital neutropenia/acute myeloid leukemia, is required for SH2-containing phosphatase-1 suppression of Stat activation. J Immunol 2001;167:6447-52.
23. van de Geijn GJ, Gits J, Aarts LH, Heijmans-Antonissen C, Touw IP. G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact. Blood 2004;104:667-74.
24. Ward AC, van Aesch YM, Schelen AM, Touw IP. Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia. Blood 1999;93:447-58.
25. Hermans MH, Ward AC, Antonissen C, Karis A, Löwenberg B, Touw IP. Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. Blood 1998;92:32-9.
26. Hunter MG, Avalos BR. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival. Blood 2000;95:2132-7.
27. Mitsui T, Watanabe S, Taniguchi Y, et al. Impaired neutrophil maturation in truncated murine G-CSF receptor-transgenic mice. Blood 2003;101:2990-5.
28. Corey SJ, Dombrosky-Ferlan PM, Zuo S, et al. Requirement of Src kinase Lyn for induction of DNA synthesis by granulocyte colony-stimulating factor. J Biol Chem 1998;273:3230-5.
29. Corey SJ, Burkhardt AL, Bolen JB, Geahlen RL, Tkatch LS, Tweardy DJ. Granulocyte colony-stimulating factor receptor signaling involves the formation of a three-component complex with Lyn and Syk protein-tyrosine kinases. Proc Natl Acad Sci U S A 1994;91:4683-7.
30. Futami M, Zhu QS, Whichard ZL, et al. G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase. Blood 2011;118:1077-86.
31. Zhu QS, Robinson LJ, Roginskaya V, Corey SJ. G-CSF-induced tyrosine phosphorylation of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not proliferative, responses. Blood 2004;103:3305-12.
32. Plo I, Zhang Y, Le Couédic JP, et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med 2009;206:1701-7.
33. Bicocca VT, Chang BH, Masouleh BK, et al. Crosstalk between ROR1 and the pre-B-cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012;22:656-67.
34. Tyner JW, Deininger MW, Loriaux MM, et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A 2009;106:8695-700.
35. Tyner JW, Yang WF, Bankhead A III, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res 2013;73:285-96.
36. Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011;29:1046-51.
37. Hunter MG, Avalos BR. Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. Blood 1999;93:440-6.
38. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17.
39. Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013;45:18-24.
40. Kunter G, Woloszynek JR, Link DC. A truncation mutant of CSF3R cooperates with PML-RARalpha to induce acute myeloid leukemia in mice. Exp Hematol 2011;39:1136-43.